Skip to main content
. 2021 May 5;125(1):94–100. doi: 10.1038/s41416-021-01399-6

Fig. 2. Longitudinal disease monitoring in two mCRC patients by liquid biopsy evaluation.

Fig. 2

In the first subject (a) CTCs disappear from the circulation at 40 days while two mutations in KRAS and APC detected in cfDNA indicate an increase of tumour cfDNA during treatment. In the timeline, therapy and in vivo analysis test schedule is also reported for a better framing of results. Tumour cfDNA seems to anticipate conventional diagnostic tools in predicting PD. In the second patient (b) the appearance of one CTC at 90 days corresponds to progression of the disease (PD).